Your session is about to expire
← Back to Search
PF-04457845 for Cannabis Use Disorder (FAAH-I MULTI Trial)
FAAH-I MULTI Trial Summary
This trial is testing a new drug to treat cannabis use disorder. It is 8 weeks long, and people taking the drug will be compared to those taking a placebo.
- Cannabis Use Disorder
FAAH-I MULTI Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowFAAH-I MULTI Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.FAAH-I MULTI Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
How many individuals are being helped by this medical research?
"The clinical trial is currently recruiting patients and was last updated on February 9th, 2022. The study is looking for 237 participants from 5 different sites."
Are there any open positions for patients in this particular clinical trial?
"The clinical trial is presently recruiting patients, with the posting date being 1/14/2019 and the most recent edit on 2/9/2022."
Could you please list other scientific research that has been completed on PF-04457845?
"PF-04457845 was first studied in 2019 by researchers at Johns Hopkins University. So far, there have been a total of 174 completed trials. As of now, there is 1 active study, with many of these studies taking place in New york City."
Does this research project include elderly individuals as test subjects?
"From the information provided by the study's inclusion criteria, the minimum age requirement for participants is 18 and the maximum is 60."
If I qualify, may I take part in this experiment?
"The trial team is looking for 237 individuals aged 18-60 who have cannabis use disorders."
Has PF-04457845 received regulatory approval from the FDA?
"PF-04457845 is still being tested for efficacy in Phase 2 trials, so it only received a safety score of 2."
On how many different continents is this research project being conducted?
"In addition to other research sites, this clinical trial is enrolling patients at Johns Hopkins in New york City, Columbia University Medical College / New York State Psychiatric Institute in Charleston, South carolina, and the Medical University of South Carolina in New Haven, Connecticut."
Share this study with friends
Copy Link
Messenger